A 24-Week Randomised, Double-Blind, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Insulin
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)
AstraZeneca Galida Medical Sciences Director, MD
Study Director
AstraZeneca
United States: Food and Drug Administration
D6160C00033
NCT00242372
August 2004
March 2006
Name | Location |
---|---|
Research Site | Alabaster, Alabama |
Research Site | Mesa, Arizona |
Research Site | Anaheim, California |
Research Site | Danbury, Connecticut |
Research Site | Washington, District of Columbia |
Research Site | Boca Raton, Florida |
Research Site | Albany, Georgia |
Research Site | Boise, Idaho |
Research Site | Arlington Heights, Illinois |
Research Site | Bloomington, Indiana |
Research Site | Hays, Kansas |
Research Site | Baton Rouge, Louisiana |
Research Site | Baltimore, Maryland |
Research Site | Battle Kreek, Michigan |
Research Site | Branson, Missouri |
Research Site | Grand Island, Nebraska |
Research Site | Las Vegas, Nevada |
Research Site | Hooksett, New Hampshire |
Research Site | Belleville, New Jersey |
Research Site | Albuquerque, New Mexico |
Research Site | Albany, New York |
Research Site | Asheville, North Carolina |
Research Site | Akron, Ohio |
Research Site | Enid, Oklahoma |
Research Site | Bend, Oregon |
Research Site | Allentown, Pennsylvania |
Research Site | Charleston, South Carolina |
Research Site | Abilene, Texas |
Research Site | Abington, Virginia |
Research Site | Auburn, Washington |
Research Site | Appleton, Wisconsin |